Obalon Therapeutics, Inc.
OBLN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $1 | $8 |
| % Growth | -97.2% | 11.6% | -86% | – |
| Cost of Goods Sold | $0 | $1 | $0 | $3 |
| Gross Profit | $0 | $1 | $1 | $5 |
| % Margin | 52.1% | 48.2% | 61.2% | 62.9% |
| R&D Expenses | $0 | $0 | $0 | $2 |
| G&A Expenses | $0 | $2 | $2 | $6 |
| SG&A Expenses | $1 | $2 | $2 | $5 |
| Sales & Mktg Exp. | $0 | $1 | $1 | $3 |
| Other Operating Expenses | $8 | $0 | $0 | $0 |
| Operating Expenses | $9 | $3 | $3 | $6 |
| Operating Income | -$9 | -$2 | -$2 | $3 |
| % Margin | -24,714% | -170.6% | -165.2% | 31.8% |
| Other Income/Exp. Net | -$0 | -$1 | $3 | -$4 |
| Pre-Tax Income | -$9 | -$3 | $1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$3 | $1 | -$2 |
| % Margin | -24,822.5% | -211.8% | 132.4% | -20.6% |
| EPS | 0 | -2.25 | 18.98 | -13.22 |
| % Growth | 100% | -111.9% | 243.6% | – |
| EPS Diluted | 0 | -2.25 | 18.98 | -13.22 |
| Weighted Avg Shares Out | 0 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 0 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$9 | -$2 | -$2 | -$2 |
| % Margin | -24,740.5% | -170.6% | -165.2% | -23.2% |